Compare ADAM & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADAM | WVE |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 673.2M | 744.8M |
| IPO Year | 2003 | 2015 |
| Metric | ADAM | WVE |
|---|---|---|
| Price | $7.64 | $3.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 19 |
| Target Price | $12.04 | ★ $18.06 |
| AVG Volume (30 Days) | 1.2M | ★ 2.9M |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | ★ 14.08% | N/A |
| EPS Growth | ★ 196.49 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | N/A | $19.21 |
| Revenue Next Year | $5.45 | N/A |
| P/E Ratio | $8.82 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $6.45 | $3.27 |
| 52 Week High | $10.36 | $21.73 |
| Indicator | ADAM | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 22.02 | 20.10 |
| Support Level | $7.05 | N/A |
| Resistance Level | $7.80 | $6.33 |
| Average True Range (ATR) | 0.22 | 0.19 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 23.08 | 2.53 |
Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.